Canyon Pharmaceuticals announced that Iprivask (desirudin for injection), a direct thrombin inhibitor, has been made available for the prevention of deep vein thrombosis (DVT), which may lead to pulmonary embolism, in patients undergoing elective hip replacement surgery. Iprivask was originally approved by the FDA based on data from head-to-head trials that found Iprivask to be superior to both heparin and low-molecular weight heparin (LMWH) enoxaparin for the prevention of proximal DVT and for major venous thromboembolic events (VTE) after elective hip replacement surgery.

For more information call (888) 434-7003 or visit